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3. SUMMARY 
 
Measurement of prostate specific antigen (PSA) is a very sensitive method for diagnosing and 
monitoring of prostate cancer (PCa), but the specificity needs improvement. Measurements of 
different molecular forms of PSA have been shown to improve differentiation between PCa 
and benign prostatic diseases. However, accurate measurement of some isoforms has not been 
achieved in previous assays. The aim of the present study was to develop new assays that 
reliably measure enzymatically active PSA, PSA-1-chymotrypsin (PSA-ACT) and PSA-1-
protease inhibitor (PSA-API), and to evaluate their diagnostic value.  
We produced a novel monoclonal antibody (MAb), with better specificity for PSA-
ACT and reduced reactivity with free ACT and cathepsin G-ACT. Double-label 
immunofluorometric assays using this MAb and another antibody to either free PSA (fPSA) 
or total PSA (tPSA) were developed and used to measure PSA-ACT and fPSA or tPSA at the 
same time. These assays provide enough sensitivity for measurement of PSA-ACT in sera 
with low PSA levels.
 
The results obtained confirmed that proportion of PSA-ACT to tPSA 
(%PSA-ACT) was as useful as proportion of fPSA to tPSA (%fPSA) for discrimination 
between PCa and
 
benign prostatic hyperplasia (BPH).  
We developed an immunoassay for detection of PSA-API based on proximity ligation, 
which improved assay sensitivity 10-fold compared with conventional assays. A new anti API 
MAb together with an anti PSA MAb were used to detect PSA-API captured on the solid 
phase by another anti PSA MAb. Concentrations of PSA-API in serum samples with tPSA 
concentrations of 4-10 g/L could be reliably measured. Our results confirmed previous 
findings that the PSA-API level is somewhat lower in men with than without PCa, and the 
combination of %fPSA and proportion of PSA-API to tPSA (%PSA-API) provides diagnostic 
improvement compared with either method alone. Assays based on this principle should be 
applicable to other immunoassays in which the nonspecific background is a problem. 
Enzymatically active PSA has been shown to be a potential marker for PCa. A PSA-
binding peptide fusion protein labeled with Eu
3+
 was used as a tracer to develop an 
immunopeptidometric sandwich
 
assay for measurement of enzymatically active PSA. This 
assay showed high specificity, but sensitivity was not good enough for measurement of PSA 
concentrations in the gray zone, 2-10 g/L, in which tPSA does not efficiently differentiate 
between PCa and BPH. To improve sensitivity, we further developed a solid-phase proximity 
ligation immunoassay. A PSA-binding peptide and an anti PSA MAb were conjugated with 
DNA probes and used to detect active PSA immobilized on a solid phase by another anti PSA 
MAb. This assay provided a 10-fold improvement in sensitivity but an even higher sensitivity 
is needed to analyze serum samples with low PSA concentrations. This proof of concept study 
shows that peptides reacting with proteins are potentially useful for sensitive and specific 
measurement of protein variants for which specific MAbs cannot be obtained.  
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4. REVIEW OF THE LITERATURE  
 
4.1 Prostate cancer  
4.1.1 Epidemiology 
 
Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer and second leading 
cause of cancer-related death of men in developed countries. Both incidence and mortality
 
rates of PCa are highest in North America, and Northern and Western Europe, but much lower 
in Asia and Northern Africa (Jemal et al., 2006; Parkin et al., 2005; Postma & Schroder, 
2005) (Fig. 1). It has been estimated in 2008 that PCa alone accounts
 
for about 25% (186,320) 
of all newly diagnosed cancers and 10% (28,660) of all male cancer deaths in the USA (Jemal 
et al., 2008). In Finland the PCa incidence and mortality have been increasing since the 
1960’s (Fig. 2). The highest incidence was detected in 2006, when 4630 new cases of PCa 
were diagnosed. In 2007, 4189 new cases of PCa were reported, which corresponds to an 
incidence of 85.7 per 100,000 population. PCa ranks first of all male cancers, and accounts 
for 31.8% of new cancer cases in men; and it caused in 793 deaths, which corresponds to 
13.8% of all causes of male cancer death, making PCa the second most common cause of 
male cancer death after lung cancer (Finnish Cancer Registry, 2009).   
Incidence and mortality rates of PCa in black males is higher than that in white men, 
who have a higher rate than men of Asian origin in USA (Jemal et al., 2008). Differences in 
genetic variants (Corder et al., 1995; Devgan et al., 1997; Irvine et al., 1995; Platz et al., 2000; 
Shook et al., 2007), serum level of sex hormones (Ross et al., 1986; Ross et al., 1992; Winters 
et al., 2001; Wu et al., 2001a) and growth factors (Tricoli JV 1999, Platz EA 1999, Winter DL 
2001) may contribute to racial differences in PCa incidence.  
PCa is a slowly growing cancer (Carter et al., 1992a; Schmid et al., 1993; Stenman et 
al., 1999a), and incidence and mortality rates increase dramatically in men over 50 years of 
age (Fig. 3). In Finland, the median age of PCa at presentation is about 70 years while it is 
about 67.2 years in the USA (Finnish Cancer Registry, 2009; Shao et al., 2009). 
 
 
 
 
Figure 1. Age-standardized incidence and mortality rates for PCa, per 100,000 men (Parkin et 
al., 2005). Reprinted with permission from John Wiley & Sons Inc. 
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Figure 2. PCa Incidence and mortality in 
1960-2007 in Finland (Finnish Cancer 
Registry, 2009). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. PCa Incidence rates and 
mortality rates by age in 2002-2007 in 
Finland (Finland Cancer Registry, 2009). 
 
4.1.2 Risk factors  
 
The etiology of PCa remains inconclusive. Many endogenous and environmental factors are 
linked to PCa risk, and some of them have been confirmed by epidemiologic studies 
(Bostwick et al., 2004; Schaid, 2004).    
4.1.2.1 Genetic factors 
 
Family history is associated with PCa risk (Ahn et al., 2008b; Hemminki & Dong, 2000; 
Negri et al., 2005). Men who have first-degree or second-degree relatives with PCa have an 
increased risk of PCa (Bruner et al., 2003; Johns & Houlston, 2003). Furthermore, there are 
ethnic differences in incidence and mortality in different populations (Jemal et al., 2008). This 
suggests that genetic factors play a critical role in PCa initiation and progression (Gronberg et 
al., 1994). A number of genetic alterations have been implicated in the development of PCa 
(Dong, 2006; Gsur et al., 2004; Schaid, 2004). 
More recently, genome-wide association studies (GWAS) have provided a new 
approach to identify disease alleles. Large numbers of single nucleotide polymorphisms 
(SNPs) in the human genome have been analyzed to assess the association of the SNPs with 
PCa (Eeles et al., 2008; Witte, 2009; Zheng et al., 2008). Loci associated with PCa have been 
identified on chromosome 2q15 (Gudmundsson et al., 2008), chromosome 8q24 
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(Gudmundsson et al., 2007a; Haiman et al., 2007; Yeager et al., 2007; Zheng et al., 2008), 
chromosome 10 (Eeles et al., 2008; Thomas et al., 2008), and chromosome 17 (Gudmundsson 
et al., 2007b; Sun et al., 2008; Zheng et al., 2008). These loci contain some candidate 
susceptibility genes: -microseminoprotein (MSMB) gene (Chang et al., 2009; Thomas et al., 
2008), lemur tyrosine kinase 2 (LMTK2) gene (Eeles et al., 2008), kallikrein 3 (KLK3) gene 
(Ahn et al., 2008a; Eeles et al., 2008; Pal et al., 2007), Disabled homolog 2 interacting protein  
(DAB2IP) gene (Duggan et al., 2007), and hepatocyte
 
nuclear factor 1 homeobox B (HNF1B) 
gene (Sun et al., 2008).  
Recurrent chromosomal rearrangements may cause gene fusions. Recent experimental 
evidences suggest that gene fusions are key events driving the development and progression 
of PCa (Kumar-Sinha et al., 2008). In PCa, genomic rearrangements occur between the 5’ 
untranslated end of transmembrane protease, serine 2 (TMPRSS2), a prostate-specific and 
androgen receptor-regulated gene, and the E26 transformation-specific family of genes (ETS 
family genes) that are oncogenic transcription factors (Tomlins et al., 2005). Of the ETS 
family, ERG (ETS-related gene) and ETV1 (ETS-variant genes 1) are observed in about half 
of all PCa cases with TMPRSS2-ETS fusion (Hermans et al., 2006; Mehra et al., 2008; Perner 
et al., 2006; Tomlins et al., 2005).  
4.1.2.2 Endogenous factors 
 
Many endogenous, non-genetic factors also affect the development of PCa. These include 
hormones and growth factors. High levels of circulating testosterone and low levels of sex 
hormone-binding globulin are associated with increased
 
risks of PCa (Gann et al., 1996). High 
testosterone concentrations in blood have been found to be associated with an increased risk 
for low grade PCa but with a reduced risk for high grade PCa (Platz et al., 2005; Schatzl et al., 
2001). A higher ratio of testosterone to sex hormone–binding globulin is related to an 
increased risk primarily in men 65 years of age or older (Weiss et al., 2008). However, other 
studies find no relationship between PCa and sex hormones (Eaton et al., 1999; Roddam et 
al., 2008a). 
Increased PCa risk has been reported to be associated with elevated plasma Insulin-
like growth factor 1 (IGF-1) and decreased Insulin-like growth factor binding protein-3 
(IGFBP-3) levels (Chan et al., 1998; Renehan et al., 2004; Roddam et al., 2008b; Stattin et al., 
2000) although this is not found in other studies (Finne et al., 2000a; Weiss et al., 2007). 
Some studies indicate that IGF-1 is related to benign prostate hyperplasia (BPH) rather than 
PCa (Colao et al., 1999; Finne et al., 2000a).  
PCa risk has been reported to be positively associated with body mass index (BMI) 
(Engeland et al., 2003; Rodriguez et al., 2001; Strom et al., 2008), waist to hip ratio (Hsing et 
al., 2000; Hubbard et al., 2004; Pischon et al., 2008), and high birth weight and length (Nilsen 
et al., 2005; Zuccolo et al., 2008). In contrast, men with diabetes have a lower risk of PCa 
(Bonovas et al., 2004; Leitzmann et al., 2008; Rodriguez et al., 2005). This may be associated 
with serum levels of sex hormones and growth factors (Buschemeyer & Freedland, 2007; 
Ding et al., 2006; Rogers et al., 2006). 
4.1.2.3 Exogenous factors 
 
There is large geographic variation in PCa incidence (Baade et al., 2004), and the incidence 
increases markedly in migrants who move from low risk countries to areas of higher risk 
(Beiki et al., 2008; Shimizu et al., 1991; Stellman & Wang, 1994; Yu et al., 1991). Some 
studies have suggested that exogenous factors are involved in the etiology of PCa 
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(Giovannucci et al., 2007). This is also supported by a twin study assessing the impact of 
heredity on cancer (Lichtenstein et al., 2000). 
Diet Red meat consumption is positively associated with risk of PCa (Giovannucci et 
al., 1993; Koutros et al., 2008; Michaud et al., 2001; Schuurman et al., 1999), while 
consumption of fish may reduce the risk of PCa (Augustsson et al., 2003; Norrish et al., 1999; 
Terry et al., 2001). High consumption of vegetables, including cruciferous vegetables (Cohen 
et al., 2000; Jain et al., 1999; Kirsh et al., 2007), carrot (Kolonel et al., 2000), cabbage (Hebert 
et al., 1998), tomato (Bosetti et al., 2000; Giovannucci et al., 1995; Giovannucci et al., 2002) 
and soy (Kurahashi et al., 2007; Lee et al., 2003; Yan & Spitznagel, 2005), has been found to 
be associated with reduced PCa risk.  Some studies show that the risk of PCa decreases
 
with 
increasing consumption of green tea (Jain et al., 1998; Jian et al., 2004; Kurahashi et al., 
2008), a high intake of vitamin E (Heinonen et al., 1998; Huang et al., 2003; Kirsh et al., 
2006; Weinstein et al., 2005), and selenium intake (Etminan et al., 2005; Sabichi et al., 2006; 
van den Brandt et al., 2003).  
Lifestyle Some studies have found that PCa incidence is positively associated with 
alcohol consumption (Middleton Fillmore et al., 2009; Platz et al., 2004; Sesso et al., 2001) 
and smoking (Gong et al., 2008; Malila et al., 2006; Plaskon et al., 2003; Sharpe & 
Siemiatycki, 2001). Epidemiologic evidence suggests that exposure to occupational 
agrochemicals (Alavanja et al., 2003; Strom et al., 2008; Van Maele-Fabry et al., 2006) and 
occupational chemicals (Agalliu et al., 2005; Krishnadasan et al., 2007; Rybicki et al., 2006) 
is related to increased PCa risk, while occupational physical activity is inversely associated 
with PCa incidence (Krishnadasan et al., 2008; Sass-Kortsak et al., 2007).  
 
4.1.3 Diagnosis 
 
Early detection
 
and treatment of PCa may reduce mortality (Espey et al., 2007; Jemal et al., 
2004; Martin et al., 2008). When detected at a localized stage, PCa is mostly curable, while 
survival is poor at the metastatic stage (Jemal et al., 2008). The American Cancer Society and 
the American Urological Association recommend that all men have yearly PCa screening 
beginning at 50 years of age (Bryant & Hamdy, 2008; Smith et al., 2008).  
Primary care physicians have used digital rectal examination (DRE) to identify 
patients who need a prostate biopsy. DRE may eliminate unnecessary biopsies in selective 
screening procedures (Gosselaar et al., 2008b), but the procedure is not standardized and 
results vary widely (Kripalani et al., 1996; Phillips & Thompson, 1991), and the sensitivity 
and positive predictive value of DRE are low in patients with a serum PSA < 4 g/L 
(Schroder et al., 2000; Schroder et al., 1998). Transrectal ultrasound (TRUS) provides a more 
precise estimate of prostate volume than DRE (Rietbergen et al., 1998). It is used to guide 
prostate biopsy and has greatly increased the diagnostic accuracy of this procedure (Berger et 
al., 2004; Gosselaar et al., 2008a; Uno et al., 2008).  
Determination of PSA in serum has become the primary test for identification of men 
with increased risk of PCa since it was introduced more than 20 years ago. Increased PSA 
levels are associated with increasing risk of PCa, and it is less likely that the cancer will be 
curable when the PSA level is high (Hudson et al., 1989; Stamey et al., 1987; Stenman et al., 
1994).  
Prostate biopsy under TRUS guidance is used to detect PCa in men with increased 
PSA level or abnormal DRE. Sextant biopsy has been the standard procedure (Hodge et al., 
1989), but recently, more biopsy cores are used to improve the diagnostic accuracy (Ravery et 
al., 2008; Scattoni et al., 2008; Singh et al., 2004). The more biopsy cores are taken, the more 
cancers will be found (Guichard et al., 2007). 
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4.1.4 Classification 
 
The TNM staging system is used to classify solid tumors. T (tumor extent), N (regional lymph 
node status), and M (the presence or absence of distant metastasis) describe the extent of 
disease (Schroder et al., 1992; Sobin & Wittekind, 2002) (Table 1). 
The Gleason grading system is the most commonly used for histopathological 
classification (Epstein et al., 2006; Gleason, 1966). Gleason grade is expressed by a score, 
which is assigned to cancerous tissue based on its microscopic appearance. The two most 
dominant patterns of cells are graded on scale of 1-5 and added together to determine the 
Gleason score. PCa mortality and tumor aggressiveness are strongly associated with the 
Gleason score (Albertsen et al., 1998). A Gleason score < 7 is associated with good prognosis 
while a score of 7 or higher indicates aggressive diseases. 
 
Table 1. TNM classification for PCa (Frankel et al., 2003). Reprinted with permission from 
Elsevier. 
 
Classification Description 
T1 Not palpable or visible 
T1a  5% involved on a TURP sample 
T1b > 5% involved on a TURP sample 
T1c Needle biopsy positive (usually diagnosed because of high PSA) 
T2 Confined within prostate 
T2a  half of one lobe 
T2b > half of one lobe 
T2c Both lobes 
T3 Outside prostate 
T3a Extracapsular invasions 
T3b Seminal vesicle(s) 
T4 
Fixed or invades adjacent structures: bladder neck, 
external sphincter, rectum, levator muscles, pelvic wall 
N Nodal status 
N0 No nodes 
N1 Regional lymph node(s) positive 
M Metastatic status 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
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4.1.5 Biomarkers  
 
A biomarker is a measurable indicator of a specific biological state, the presence and stage of 
disease. Biomarkers can be used clinically for screening, diagnosis and monitoring of disease 
activity to guide or assess therapy (Etzioni et al., 2003; Rifai et al., 2006). Prostatic acid 
phosphatase (PAP) was the first biomarker for PCa (Huggins, 1943). The PAP level in serum 
is elevated in metastatic PCa (Gutman & Gutman, 1938). It was widely used until PSA was 
shown to be more sensitive than PAP in the detection of PCa (Seamonds et al., 1986; Stamey 
et al., 1987).  
PSA has been widely used as a PCa marker (details are introduced in next section). 
However, non-cancerous diseases may also cause elevation of serum PSA (Armitage et al., 
1988; Guinan et al., 1987; Stamey et al., 1987). There is thus an urgent need for PCa 
biomarkers that can improve differentiation between benign and malignant disease, and detect 
potentially life-threatening tumors. 
Many novel markers have been suggested as biomarkers for PCa (Table 2). Some of 
them have shown potentially clinical value. Human glandular kallikrein 2 (hK2, also called 
KLK2) is one of 15 members of the KLK family (Yousef et al., 2001), it shares about 80% 
identity at the amino acid and DNA level with PSA (also called KLK3) (Henttu & Vihko, 
1989; Lundwall, 1989; Riegman et al., 1989b; Rittenhouse et al., 1998). Determination of 
serum hK2 may improve the specificity for detecting PCa (Becker et al., 2000; Darson et al., 
1997; Steuber et al., 2007b). TMPRSS2-ETS fusion has been found in approximately 50% of 
PCa samples (Kumar-Sinha et al., 2008). Expression of the TMPRSS2-ETS fusion in prostate 
tissue is strongly associated with specific morphological features and adverse prognosis 
(Mosquera et al., 2007; Nam et al., 2007; Tomlins et al., 2005). Prostate cancer antigen 3 
(PCA3) is a prostate-specific non-coding RNA. Recent studies have shown that the elevated 
PCA3 RNA level in urine is useful in the diagnosis for PCa (Bussemakers et al., 1999; van 
Gils et al., 2007). Serine peptidase inhibitor, Kazal type 1 (SPINK1), also known as tumor-
associated trypsin inhibitor (TATI), is a specific inhibitor of trypsin. SPINK1 expression in 
tissue is found in high-grade PCa and this is associated with adverse prognosis (Paju A 2007, 
Tomlins SA 2008).  
 
4.2 Prostate specific antigen (PSA) 
 
In 1960 various prostate specific antigens were detected in prostatic tissue extracts (Flocks et 
al., 1960). In the 1970s several independent investigators subsequently identified and 
characterized a prostate specific protein in seminal plasma. This protein was called -
seminoprotein (Hara et al., 1971), protein E (Li & Beling, 1973) or p30 (Sensabaugh, 1978). 
In 1979 Wang and coworkers purified a protein from prostate tissue and named it prostate 
specific antigen (PSA) (Wang et al., 1979).  It is now generally accepted that -seminoprotein, 
protein E, p30 and PSA are the same protein (Wang et al., 1994). PSA was detected in serum 
from men with advanced PCa in the 1980’s (Kuriyama et al., 1981; Papsidero et al., 1980). 
Since then PSA has become the most widely used serum marker for PCa (Catalona et al., 
1991; Stamey et al., 1987). 
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Table 2. Potential biomarkers for PCa and their possible clinical utility. 
 
Potential serum biomarkers Possible Clinical utility References 
Chromogranin A (CgA) Prognosis (Berruti et al., 2000; Sciarra et 
al., 2008; Taplin et al., 2005)  
Early prostate cancer antigen 
(EPCA) 
Diagnosis (Leman et al., 2007; Paul et 
al., 2005; Uetsuki et al., 2005) 
Hepatocyte growth factor 
(HGF) 
Diagnosis and Prognosis (Gupta et al., 2008; Nagakawa 
et al., 2005; Naughton et al., 
2001) 
Huntingtin-interacting protein 1 
(HIP1) 
Diagnosis (Bradley et al., 2005; Rao et 
al., 2002) 
Insulin-like growth factor 1 
(IGF-1)  
Diagnosis (Chan et al., 1998; Woodson 
et al., 2003) 
Insulin-like growth factor 
binding protein-3 (IGFBP-3) 
Diagnosis and Prognosis (Chan et al., 1998; Shariat et 
al., 2002) 
Interleukin-6 (IL6) and 
Interleukin 6 soluble receptor 
(IL6SR) 
Diagnosis (Nakashima et al., 2000; 
Shariat et al., 2001a) 
hK2 (KLK2)  Diagnosis and Prognosis (Darson et al., 1997; Partin et 
al., 1999; Steuber et al., 
2007b; Wenske et al., 2009) 
KLK11 Diagnosis (Diamandis et al., 2002; 
Nakamura et al., 2003) 
Macrophage inhibitory 
cytokine 1 (MIC-1) 
Diagnosis and Prognosis (Brown et al., 2006; Selander 
et al., 2007) 
Osteopontin Diagnosis and Prognosis (Caruso et al., 2008; Fedarko 
et al., 2001; Hotte et al., 2002; 
Ramankulov et al., 2007) 
Prostate secretory protein of 
94 amino acids (PSP94) 
Diagnosis and Prognosis (Dube et al., 1987; Nam et al., 
2006; Reeves et al., 2006) 
Trefoil factor 3 (TFF3) Diagnosis (Faith et al., 2004; Garraway 
et al., 2004; Vestergaard et al., 
2006) 
Transforming growth factor-
beta (TGF- ß1) 
Diagnosis and Prognosis (Ivanovic et al., 1995; Shariat 
et al., 2001b; Truong et al., 
1993) 
Urokinase plasminogen 
activator (uPA)/Urokinase 
plasminogen activator receptor 
(uPAR) 
Diagnosis and Prognosis (Piironen et al., 2006; Shariat 
et al., 2007; Steuber et al., 
2007a) 
 
 
Table 2. Continue. 
 
Potential urine biomarkers Possible Clinical utility References 
Prostate cancer antigen 3 
(PCA3) 
Diagnosis (Bussemakers et al., 1999; de 
Kok et al., 2002; Haese et al., 
2008; van Gils et al., 2007) 
Serine peptidase inhibitor, Kazal 
type 1 (SPINK1 or TATI)  
Diagnosis (Laxman et al., 2008; Paju et al., 
2007; Tomlins et al., 2008) 
Sarcosine Diagnosis (Sreekumar et al., 2009) 
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Table 2. Continue. 
 
Potential tissue biomarkers Possible Clinical utility References 
-methylacyl-coenzyme A racemase 
(AMACR) 
Diagnosis (Luo et al., 2002; Rubin et al., 
2002) 
Annexin A3 (ANXA3) Diagnosis (Kollermann et al., 2008; 
Schostak et al., 2009) 
Cysteine-rich secretory protein 3 
(CRISP-3) 
Diagnosis and Prognosis (Asmann et al., 2002; Bjartell 
et al., 2006; Bjartell et al., 
2007) 
Enhancer of zeste homolog 2 
(EZH2) 
Diagnosis and Prognosis (Bachmann et al., 2006; 
Laitinen et al., 2008; 
Varambally et al., 2002) 
E-cadherin (ECAD) Prognosis (Ray et al., 2006; Rhodes et 
al., 2003) 
   
Golgi phosphoprotein 2 (GOLPH2) Diagnosis (Kristiansen et al., 2008; Wei 
et al., 2008) 
Glutathione S-transferases pi 1 
(GSTP1) 
Diagnosis (Gonzalgo et al., 2003; 
Tokumaru et al., 2004) 
Hepsin Prognosis (Dhanasekaran et al., 2001; 
Magee et al., 2001; Stephan et 
al., 2004) 
Ki-67 protein Prognosis (Cowen et al., 2002; Goto et 
al., 2008)  
p27 Prognosis (Freedland et al., 2003; 
Thomas et al., 2000)  
Phosphatase and tensin homologue 
(PTEN) 
Prognosis (Majumder & Sellers, 2005; 
McCall et al., 2008) 
Proviral integration site for Molony 
murine leukaemia virus (PIM-1)  
Diagnosis and Prognosis (Dhanasekaran et al., 2001) 
(Cibull et al., 2006; Valdman et 
al., 2004)  
Prostate-specific membrane antigen 
(PSMA) 
Diagnosis and Prognosis (Birtle et al., 2005; Bostwick et 
al., 1998; Ross et al., 2003) 
Prostate stem cell antigen (PSCA) Diagnosis  (Gu et al., 2000; Han et al., 
2004) 
TMPRSS2-ETS fusion Diagnosis and Prognosis (Mosquera et al., 2008; Nam 
et al., 2007; Tomlins et al., 
2005)  
Zinc-alpha2-glycoprotein (AZGP1or 
ZAG) 
Diagnosis and Prognosis (Hale et al., 2001; Henshall et 
al., 2006; Lapointe et al., 
2004) 
 
4.2.1 Expression 
 
PSA is produced by the epithelial cells in both normal and neoplastic prostatic tissue. In the 
normal prostate, PSA is secreted into the lumen of the prostatic ducts (Qiu et al., 1990; 
Warhol & Longtine, 1985), while only small amount of PSA diffuse into circulation. Thus the  
concentration of PSA in seminal plasma is about one million-fold higher than in serum (Lilja, 
1985). Due to disruption of the glandular architecture and loose contact with the prostatic 
ducts in PCa, PSA is secreted into blood, which results in elevation of serum PSA (Stenman 
et al., 1999a). The contribution of cancerous tissue to the serum levels of PSA is larger than 
that of normal prostatic and BPH tissue (Stamey et al., 1987) although PSA expression per 
cell is lower in carcinoma than in benign prostate epithelium (Pretlow et al., 1991), and it 
decreases with increasing Gleason grade (Abrahamsson et al., 1988; Aihara et al., 1994). 
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Elevated serum PSA concentrations are also related to prostatic volume (Babaian et al., 1990; 
Roehrborn et al., 1999). PSA expression is regulated by androgens (Henttu et al., 1992; 
Riegman et al., 1991). Thus androgen ablation, a standard therapy for advanced PCa (Sharifi 
N 2005), causes a rapid drop in serum PSA (Arai et al., 1990; Stamey et al., 1989).  
PSA has been found at very low level in many tissues and body fluids (Shaw & 
Diamandis, 2007), and in some cancer tissues including lung, adrenal, kidney and colon 
(Levesque et al., 1995). The periurethral glands may produce PSA both in males and females 
(Iwakiri et al., 1993; Pollen & Dreilinger, 1984). In pregnant women amniotic fluid has been 
shown to contain low levels of PSA (Lovgren et al., 1999; Yu & Diamandis, 1995a). PSA is 
detectable in breast milk, cyst fluid and nipple aspirate fluid (Lovgren et al., 1999; Yu & 
Diamandis, 1995b). Clearly elevated PSA levels may occur in serum of females with breast 
cancer (Black et al., 2000; Diamandis, 2000; Melegos & Diamandis, 1996). However, in men 
PSA is in practice prostate specific. 
 
4.2.2 Biochemistry 
 
PSA (KLK3), also known as kallikrein-related peptidase 3, is a serine protease belonging to 
the KLK family. The PSA gene is located in chromosomal region 19q13.2-13.4 comprising all 
15 KLK genes (Riegman et al., 1989a; Yousef & Diamandis, 2001). PSA is synthesized with 
a 17 amino acid leader sequence (preproPSA) that is cleaved cotranslationally to generate the 
inactive precursor protein (proPSA) containing 244 amino acids (Lundwall & Lilja, 1987; 
Mikolajczyk et al., 1997). Cleavage of the seven N-terminal amino acids from proPSA 
generates the active enzyme. Several prostatic proteases can activate PSA, including hK2 
(Kumar et al., 1997; Lovgren et al., 1997; Takayama et al., 1997), trypsin (Paju et al., 2000; 
Takayama et al., 1997), KLK4 (Takayama et al., 2001b), and prostin/KLK15 (Takayama et 
al., 2001a; Yousef et al., 2001). 
Mature PSA is a glycoprotein with a molecular weight of 28.430 kD, which contains 
237 amino acids and one carbohydrate chain linked to asparagine 45 (Belanger et al., 1995; 
Lundwall & Lilja, 1987). The carbohydrate moiety is a biantennary complex oligosaccharide 
(Mattsson et al., 2008; Okada et al., 2001; Peracaula et al., 2003; Prakash & Robbins, 2000). 
Residues histidine 41, aspartate 96 and serine 189 form the active site of PSA. Active PSA 
has been shown to possess chymotrypsin-like substrate specificity (Watt et al., 1986). The 
best substrate for PSA contains the amino acid sequence SSIYSQTEEQ derived from the 
semenogelin sequence, in which PSA cleaves the peptide bond between Tyr (Y) and Ser (S) 
(Rehault et al., 2002). 
The zinc concentrations in the prostate are high. Zn
2+ 
at low micromolar concentration 
inhibits PSA activity (Hsieh & Cooperman, 2000; Malm et al., 2000; Watt et al., 1986). Two 
serine protease inhibitors (serpins), 1-chymotrypsin (ACT) (Mr of 68 kD) and 1-proteinase 
inhibitor (API) (Mr of 53kD), and the general protease inhibitor, 2-macroglobulin (A2M) 
(Mr of 725 kD) form complexes with PSA and inhibit the enzymatic activity of PSA in 
circulation.  
 
4.2.3 Biological function 
 
PSA is a major protein in seminal fluid and degrades the gel-forming proteins of semen, 
semenogelin 1 and 2. The physiological function of PSA is to liquefy the clot forming after 
ejaculation and cause release of motile spermatozoa (Lilja, 1985; Lilja et al., 1987). The 
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activity of PSA against commonly available peptide substrates is low, but it has been shown 
to cleave certain proteins in vitro. Cleavage by PSA results in inactivation of IGFBP-3, which 
may increase cell proliferation by releasing bound IGF-1 (Cohen et al., 1992). However, other 
prostatic proteases, like hK2 and trypsin, cleave IGFBP-3 more efficiently than PSA 
(Koistinen et al., 2002). PSA may promote cell migration and metastasis by cleaving 
fibronectin and laminin (Webber et al., 1995). PSA has also been shown to exert anti-
angiogenic activity and it may thus slow down progression of PCa (Fortier et al., 1999). In 
vitro, PSA has been shown to convert plasminogen to biologically active angiostin-like 
fragments with anti-angiogenic activity (Heidtmann et al., 1999). The anti-angiogenic effect is 
dependent on the enzymatic activity of PSA. Internally cleaved and inactive PSA is devoid of 
this activity (Mattsson et al., 2008). 
 
4.2.4 Molecular forms (Fig. 4) 
 
A majority (60-95%) of the immunoreactive PSA in plasma is complexed with 1-
chymotrypsin (PSA-ACT) (Lilja et al., 1991; Stenman et al., 1991). The PSA-1-protease 
inhibitor complex (PSA-API) represents 1-10% of the total PSA immunoreactivity (Stenman 
et al., 1991; Zhang et al., 1999). PSA-2-macroglobulin (PSA-A2M) cannot be detected by 
conventional immunoassays because PSA is engulfed by A2M, but it can be measured after 
PSA are released from the complex at a high pH. As measured by this method, PSA-A2M in 
serum represents 2-40% of total PSA (tPSA) (Zhang et al., 2000). 
A variable part (5-40%) of PSA in plasma consists of various forms of free PSA 
(fPSA) that lack enzymatic activity due to nicking. Nicked PSA in serum is mature PSA 
which is internally cleaved between residues 85 and 86, 145 and 146 or 182 and 183 (Charrier 
et al., 1999; Hilz et al., 1999; Noldus et al., 1997). BPH tissue contains a distinct degraded 
form containing peptide bond cleavages at Lys145 and Lys182, which has been termed 
benign PSA (BPSA) (Mikolajczyk et al., 2000b).  
A minor part of fPSA in plasma consists of proPSA, which lacks enzymatic activity 
and thus cannot form complexes with inhibitors (Lovgren et al., 1997; Vaisanen et al., 1999). 
proPSA represents 25-50% of fPSA in plasma (Mikolajczyk et al., 2004; Niemela et al., 
2002)). It consists of (-7)proPSA (the full-length, 7 amino acid propeptide), and truncated 
forms (-5)proPSA (5 amino acid propeptide), (-4)proPSA (4 amino acid propeptide) and (-
2)proPSA (2 amino acid propeptide) (Mikolajczyk et al., 2000a; Peter et al., 2001). Other 
truncated forms of fPSA, lacking a few amino acids at the beginning of N-terminus, have also 
been found in serum (Peter et al., 2001). Very low level of active PSA (3% of fPSA) has been 
observed in blood (Niemela et al., 2002). 
In seminal plasma about 65% of PSA is enzymatically active and about 35% is nicked 
(Zhang 1995, Mattsson JM 2008).  
 
4.2.5 Measurement of PSA 
 
The first PSA immunoassay developed in 1980 was radioimmunoassay (Kuriyama et al., 
1980). Currently available PSA assays are automated immunometric methods that facilitate 
sensitive, reliable and high-throughput analysis for screening, diagnosis, and monitoring of 
PCa. Recently, assays utilizing novel techniques, e.g., PCR or nanotechnology, have been 
developed. Some of them show higher sensitivity than conventional assays. Assays using 
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surface plasmon resonance (SPR) or microcantilevers facilitate rapid and easy determination, 
and show potential as point-of-care tests. 
 
 
 
Figure 4. Molecular forms of PSA in blood. 
 
4.2.5.1 PSA antibodies  
 
Selecting an appropriate antibody pair is important for development of PSA immunoassays. 
Monoclonal antibodies (MAbs) against PSA have been classified into 6 major groups based 
on their epitopes (Stenman et al., 1999b). Group 1 antibodies are specific for fPSA, while 
group 2-6 antibodies react with both free and complexed PSA. Specific assays for various 
forms of PSA have been developed by combining different antibodies. However, some assays 
are not equimolar, i.e., they overestimate fPSA (Roddam et al., 2006; Zhou et al., 1993). 
4.2.5.2 Standards 
 
Standardization of PSA requires common standards. The First International Standards for 
tPSA (IRR 96/670) and fPSA (IRR 96/688) were established in 1999 (Rafferty et al., 2000). 
IRR 96/670 is a mixture of PSA and ACT in a 90:10 ratio
 
mimicking circulating PSA, while 
IRR 96/688 contains fPSA. Use of these standards can help to reduce differences between 
assays (Stephan et al., 2006). 
4.2.5.3 PSA immunoassays 
 
The first commercial PSA assay (Pros-Check) was a traditional polyclonal radioimmunoassay 
(RIA) that was widely used in the early PSA studies (Yang Labortories, Bellevue, WA) 
(Stamey et al., 1987). The Hybritech Tandem-R PSA test is a sandwich-type 
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immunoradiometric assay, which is the first PSA test approved by the US Food and Drug 
Administration (FDA)  (Hybritech, San Diego, CA). Most commercial assays are 
immunoenzymetric assays or immunochemiluminometric sandwich assays, and a majority of 
them use MAbs (Table 3). A time resolved immunofluormetric assay (IFMA), which uses 
antibodies labeled with stable fluorescent lanthanide chelates as detectors, measures fPSA and 
tPSA simultaneously (DELFIA PROSTATUS) (Perkin Elmer-Wallac, Turku, Finland).  
 
Table 3. Characteristics of commercial PSA assay.  
 
 
Abbreviations: LDL, lowest detection limit; RIA, radio immunoassay; IRMA, immunoradiometric assay; 
IEMA, immunoenzymetric assay; ICMA, immunochemiluminometric assay; IFMA, immunofluorometric 
assay; ECIA, electrochemiluminescent immunoassay; M, monoclonal; P, polyclonal; ALP, alkaline 
phosphatase; AE, acridinium ester; dP, dioxetane phosphate; HRP, horseradish peroxidase; 
125
I , 
iodine-125; pNPP, para-nitrophenyl phosphate; TMB, tetramethylbenzidine; mUP, 4-methylumbelliferyl 
phosphate; Eu, europium; Sm, samarium; T, total PSA; F, free PSA; C, complexed PSA. 
 
 
4.2.5.4 Immunoassay combined with polymerase chain reaction (PCR) 
 
Immuno-PCR combining the specificity of antibodies with the sensitivity of PCR was first 
described in 1992 (Sano et al., 1992). A reporter system termed immuno-rolling circle 
amplification (RCA) has been used for sensitive detection of PSA (Schweitzer et al., 2000). 
An antibody-oligonucleotide conjugate binds to PSA that is captured on a solid surface by an 
PSA assay  Parameter 
Assay type 
 
Capture 
antibody 
 
Tracer 
antibody 
 
Signal 
molecule 
 
Substrate 
 
 
LDL (g/L) 
Yang 
Laboratories Pro-
Check assay 
RIA P  
125
I  0.25 (T) 
Cis PSA-RICAT IRMA M M 
125
I  0.04 (T, F) 
DPC IRMAcount  IRMA M M 
125
I  0.1 (T) 
Hybritech 
Tandem-R 
IRMA M M 
125
I  0.02 (T, F) 
Abbott AxAYM IEMA M M ALP mUP 0.04 (T), 0.02 (F)
Abbott IMX IEMA M P ALP mUP 0.05 (T) 
Bayer immuno-1 IEMA M P ALP pNPP 0.02 (T, C) 
Backman 
ACCESS 
IEMA M M ALP dP 0.008 (T),  
       0.005 (F) 
CanAg EIA IEMA M M HRP TMB <0.1 (T, F) 
DPC immulite IEMA P M ALP dP 0.04 (T), 0.02 (F)
Hybritech 
Tandem-E 
IEMA M M ALP pNPP <0.1 (T) 
Tosoh AIA-PACK IEMA M M ALP mUP 0.05 (T) 
Abbott 
ARCHITECT 
ICMA M M AE H2O2 0.008 (T, F) 
Bayer ACS:180 ICMA M P AE H2O2 0.09 (T) 
Bayer  
ADVIA Centaur  
ICMA M P AE H2O2 0.03 (C) 
Perkin Elmer 
(Wallac) DELFIA 
IFMA M M Eu
3+
, Sm
3+
  0.1 (T), 0.04 (F) 
Roche Elecsys ECIA M M  ruthenium tripropylamine 0.04 (T), 0.1 (F) 
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antibody. A DNA circle is hybridized to a complementary sequence in the oligonucleotide, 
and the DNA tag is amplified by RCA. The amplification results in a long DNA molecule, 
which contains hundreds of copies of the circular DNA sequence that remain attached to the 
antibody and that can be detected by fluorescent imaging. By this method, PSA has been 
detected at a concentration of 0.1 ng/L. 
Real-time PCR uses measurement of fluorescence to monitor DNA amplification and 
quantitation of DNA concentration. In an immunoassay, PSA in the samples is captured by 
one antibody and detected by another antibody labeled with a DNA strand. Amplification of 
the DNA and measurement of PSA is performed by real time PCR. The detection limit is 
4.810
5 
PSA molecules in 5 l (corresponds to 4.5 ng/L) (Link et al., 2004). 
Proximity ligation assay is a novel, sensitive and specific method for quantitation of 
proteins (Fredriksson et al., 2002; Gullberg et al., 2004). About 300 PSA molecules in 5 l 
(corresponds to 0.0028 ng/L) can be detected in a proximity ligation assay with triple-binders, 
which are a set of three proximity probes that recognize distinct epitopes on PSA 
(Schallmeiner et al., 2007). 
4.2.5.5 Assays based on two-dimensional gel electrophoresis 
 
Subforms of fPSA in serum can be separated and quantified by two-dimensional 
electrophoresis (Jung et al., 2004). PSA is extracted from serum by immunoadsorption and 
separated by two-dimensional electrophoresis. After blotted onto a membrane, PSA is 
detected with an antibody. The chemiluminescence intensities of the PSA spots are quantified 
with an image analyzer. PSA can be measured at concentration down to 0.1 g/L (Jung et al., 
2007; Tabares et al., 2007). 
4.2.5.6 Immunoassay combined with mass spectrometry  
 
PSA in serum was captured in 96-well microtiter plates with a monoclonal PSA antibody. 
Captured PSA is reduced, alkylated, and trypsin-digested in the wells, followed by extraction 
of the peptides on a C18 Ziptip. The peptides are analyzed on a linear ion-trap mass 
spectrometer and detected by product ion-monitoring mode. PSA has been detected at a 
concentration of 0.1 g/L with a coefficients of variation (CV) < 20% (Kulasingam et al., 
2008). 
4.2.5.7 Assay based on surface plasmon resonance (SPR)  
 
SPR can be used to measure proteins by detection of changes in mass concentration on a 
biospecific surface. A PSA-ACT assay based on SPR has been developed using an anti PSA-
ACT antibody immobilized on the sensor surface. The detection limit is 18.1 g/L for serum 
samples (Cao et al., 2006). The sensitivity of SPR-based assay for PSA has been improved by 
using an antibody-colloidal gold conjugate as a detector to amplify the SPR signal. A 
detection limit for PSA-ACT of 0.027 g/L (Cao & Sim, 2007) and 0.15-1 g/L for tPSA 
(Besselink et al., 2004; Huang et al., 2005) have been reported.  
4.2.5.8 Assay based on surface plasmon field-enhanced fluorescence spectroscopy (SPFS)  
 
SPFS, which combines SPR with sensitive fluorescence detection, uses the enhanced optical 
field of a surface plasmon mode at the metal-liquid interface to excite fluorescent molecules. 
In a SPFS-based assay, an anti PSA antibody is immobilized on the SPR sensor surface as a 
 22 
capture antibody. A second anti PSA antibody labeled with fluorophores is used to detect 
PSA. A detection limit of 2 ng/L has been obtained (Yu et al., 2004). 
4.2.5.9 Assays using an amperometric biosensor 
 
PSA in samples is captured on an electrode surface containing glucose oxidase, and a PSA 
antibody-horseradish peroxidase (HRP) conjugate is used as a tracer. The concentration of 
PSA is determined by measuring changes in current caused by the enzymatic reaction of HRP. 
The limit of detection is 0.25 g/L (Sarkar et al., 2002). In another PSA assay, Poly (1,2-
diaminobenzene) is deposited on screen-printed electrodes to form an insulating layer. 
Polyaniline is electropolymerized in pores of the insulating layer produced by sonochemical 
ablation to form a microelectrode array. An anti PSA antibody is immobilized on conductive 
polyaniline protrusions. After binding of PSA to the antibody, alternating current impedance 
is used to measure the concentration of PSA. The detection limit of this assay is 1 ng/L 
(Barton et al., 2008). 
4.2.5.10 Nanotechnology-based assays  
 
Nanotechnology based on one-to-one interactions between analytes and signal-generating 
particles has shown potential utility in clinical diagnostics. PSA assays using nanotechnology 
have been developed and show high sensitivity (Table 4), e.g., immunoassays using 
fluorescent nanoparticles, composed of lanthanide chelates and polystyrene latex (Soukka et 
al., 2001), silica-coated material nanoparticles (Ye et al., 2004), or up-converting phosphor 
particles (UCP-particles) (Ukonaho et al., 2007), have shown to be 10-1000-fold more 
sensitive as compared to the conventional IFMA. Biobarcode is a nanoparticle probe 
composed of an oligonucleotide and an antibody. After PSA is bound to the magnetic 
microparticles, barcode DNA is dehybridized and amplified by PCR. A detection limit of 
0.001 ng/L has been reported (Nam et al., 2003). However, the application for routine clinical 
use needs to be confirmed. 
 
4.2.6 Clinical use of PSA  
 
PSA has been widely used as a biomarker for PCa, both for diagnosis and monitoring of PCa, 
and it is considered the most useful of all existing tumor markers. A high PSA level in serum 
is usually associated with large tumor volume, high pathological stage and high Gleason 
grade (Antenor et al., 2005; Catalona et al., 1993; Catalona et al., 1991; Stamey et al., 1987).  
4.2.6.1 Diagnosis of PCa 
 
The serum concentration of PSA shows to increase in 5-10 years before a PCa is diagnosed on 
the basis of symptoms (Carter et al., 1992b; Stenman et al., 1994). It is therefore possible to 
detect PCa at a preclinical state by performing prostate biopsy in patients with an elevated 
serum PSA. FDA approved the PSA test as an aid for early PCa detection in 1994. Men are 
advised to have a biopsy when the PSA level in serum exceeds 4
 
g/L (Catalona et al., 1994; 
Smith et al., 2006). The positive predictive value of a PSA level of above 4 g/L is about 27% 
in the Europen screening studies (Hugosson et al., 2004; Makinen et al., 2004; Postma et al., 
2007), and about 18% in screening trial in the USA (Andriole et al., 2005; Grubb et al., 2008). 
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Table 4. Assays based on nanotechnology. 
 
Signal transduction Nanoparticle or 
nanostructure 
Lowest detection 
limit (ng/L) 
Reference 
Fluorescent 
nanoparticle 
Silica-coated 
nanoparticle 
7 (Ye et al., 2004) 
 UCP-particle 0.53 (Ukonaho et al., 2007) 
 Polystyrene latex 
nanoparticle 
0.04 (Soukka et al., 2001) 
Biobarcode Gold nanoparticle 0.01 (Bao et al., 2006) 
 Gold nanoparticle 0.001 (Nam et al., 2003) 
SERS Gold nanoparticle 1 (Grubisha et al., 2003) 
SPR Colloidal gold 
nanoparticle 
<1000 (Huang et al., 2005) 
 Colloidal gold 
nanoparticle 
150 (Besselink et al., 
2004) 
 Colloidal gold 
Nanoparticle 
27  
(PSA-ACT) 
(Cao & Sim, 2007) 
Electrochemical signal Quantum dot 200 (Wang et al., 2008) 
 Quantum dot 20 (Liu et al., 2007) 
 Gold nanoparticle 0.5 (Mani et al., 2009) 
 Nanotube 250 (Okuno et al., 2007) 
 Nanotube 4 (Yu et al., 2006) 
 Nanowire 0.9 (Zheng et al., 2005) 
 Microcantilever 1000 (Yue et al., 2008) 
 Microcantilever 200 (Wu et al., 2001b) 
Abbreviations: SERS, Surface-enhanced Raman scattering; SPR, Surface plasmon resonance; SPFS, 
surface plasmon field-enhanced fluorescence spectroscopy; UCP-particle, up-converting phosphor 
particles. 
 
 
Approximately 75% of cancers are clinically organ-confined and potentially curable when 
PSA is in the range 4-10 g/L (Catalona et al., 1994; Catalona et al., 1991; Labrie et al., 
1992). Recent studies have shown that PCa can be detected in about 15% of men with PSA 
levels of less than 2 g/L, and 15% of the cancers are high grade (Gleason grade  7) 
(Thompson et al., 2004). Some experts recommend biopsy for men with PSA above 2.5 g/L, 
which significantly increases sensitivity (Catalona et al., 1997; Punglia et al., 2003). 
In many developed countries the widespread use of PSA-testing has led to increased 
incidence of PCa with a decreased proportion of aggressive PCa (Aus et al., 2007; Laurila et 
al., 2009; Pelzer et al., 2008). However, the benefit of PCa screening is still debated (Bryant 
& Hamdy, 2008; Lin et al., 2008). PSA testing leads to overdiagnosis, i.e., the detection of 
cancer that otherwise would not have been diagnosed within the patient's lifetime (Schroder, 
1995; Telesca et al., 2008). Overdiagnosis results in overtreatment, e.g., detection of 
insignificant cancers, creating patient anxiety and unnecessary costs (Draisma et al., 2003; 
McGregor et al., 1998). Results from two large randomized screening trials have recently 
been published. The US trial, the Prostate, Lung, Colorectal, and Ovarian screening trial 
(PLCO trial), is a multicenter, randomized,
 
two-arm trial comprising 154 934 women and men 
aged 55–74 (Prorok et al., 2000). The European Randomized Study of Screening for Prostate 
Cancer (ERSPC) comprises approximately 193 000 recruited men from eight countries, which 
are randomly assigned to screening tests versus community patterns of care (de Koning et al., 
2002). The results of ERSPC show that PSA screening reduces mortality from PCa, but 48 
patients need to be treated in order to save the life of one patient (Schroder et al., 2009). In the 
PLCO trial, no reduction in mortality was observed (Andriole et al., 2009). 
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4.2.6.2 Monitoring of PCa after radical therapy 
 
The FDA approved PSA as a marker to predict the risk of recurrence after treatment in 1986. 
A serum PSA
 
of at least 0.4 g/L and rising has been suggested as the standard for defining 
biochemical recurrence of PCa after radical prostatectomy (Stephenson et al., 2006a). 
Biochemical recurrence after radiation therapy has been defined as a PSA greater than the 
absolute nadir plus 2 g/L or 2 consecutive increase of at least 0.5 g/L (Horwitz et al., 
2005).  
 
4.3 Improving the clinical utility of PSA 
 
PSA is not a cancer-specific biomarker. In addition to PCa, prostatitis, BPH and other 
conditions can also increase serum PSA (Stamey et al., 1987). Determinations of various 
forms of PSA and calculated parameters have been introduced to improve the diagnostic 
accuracy of the PSA test. 
 
4.3.1 Various molecular forms of PSA in serum  
 
In 1991 PSA was found to exist in different forms in serum, about 60-95% occurring as a 
complex with ACT, 5-40% being free and a small part being a complex with API. The 
proportion of PSA-ACT (%PSA-ACT) is higher and the proportion of fPSA  (%fPSA) is 
lower in men with PCa than in those with BPH (Lilja et al., 1991; Stenman et al., 1991). 
Subsequent studies showed that a high %fPSA (e.g. >25%) is associated with reduced 
probability of PCa, while a low %fPSA (e.g. <10%) greatly increases the probability of PCa 
(Catalona et al., 1998; Catalona et al., 1995; Christensson et al., 1993). %fPSA is furthermore 
inversely correlated with tumor volume and Gleason score (Elgamal et al., 1996; Grossklaus 
et al., 2002; Southwick et al., 1999). FDA approved the fPSA test for PCa detection in 1998. 
Measurement of %fPSA increases the diagnostic accuracy at tPSA level both above 4 g/L 
(Catalona et al., 1995; Luderer et al., 1995; Partin et al., 1996) and below 4 g/L (Catalona et 
al., 1997; Finne et al., 2008; Walz et al., 2008).  
The higher expression of ACT in malignant prostatic tissue (Bjork et al., 1994) and 
higher enzymatic activity of PSA secreted by PCa (Stenman et al., 1999a) can explain higher 
PSA-ACT level in serum from men with PCa than those without PCa. Determinations of 
PSA-ACT and %PSA-ACT improve the discrimination between PCa and BPH (Christensson 
et al., 1993; Kikuchi et al., 2006; Leinonen et al., 1993; Saika et al., 2002; Stenman et al., 
1991). The proportion of PSA-API (%PSA-API) is higher in BPH than in cancer sera (Zhang 
et al., 1999). Measurement of %PSA-API has been shown to improve the clinical validity in 
PSA level above 4 g/L. However, PSA-API cannot be reliably detected in samples with low 
PSA values (Finne et al., 2000b). Measurement of complexed PSA (cPSA), which includes 
PSA-ACT and PSA-API, has shown to improve the specificity of PCa (Allard et al., 1998; 
Miller et al., 2001; Okihara et al., 2006; Partin et al., 2003), but this has not been confirmed in 
other studies (Lein et al., 2003). This may be explained by the fact that the cPSA assay 
recognizes both PSA-ACT and PSA-API, which change in different directions in PCa 
(Stenman et al., 1991; Zhang et al., 1999). 
PSA-A2M in serum cannot be detected by conventional immunoassays because A2M 
encapsulates PSA and hinders access of anti-PSA antibodies to PSA (Leinonen et al., 1996; 
Lilja et al., 1991). In a specific immunoassay, immunoreactive PSA is removed from serum 
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by immunoadsorption, and PSA-A2M is then denatured at high pH. The released PSA can be 
measured by a conventional PSA immunoassay. The proportion of PSA-A2M to tPSA is 
higher in patients with BPH than in those with PCa (Zhang et al., 1998). Measurement of the 
ratio of PSA-A2M to tPSA improves the diagnostic validity of PCa (Zhang et al., 2000). 
proPSA represents about 30% of fPSA in PCa serum (Mikolajczyk & Rittenhouse, 
2003). The (-2)proPSA level is higher in serum from patient with PCa than that with BPH 
(Chan et al., 2003; Mikolajczyk et al., 2001; Mikolajczyk et al., 2000a). Measurement of 
serum (-2)proPSA improves detection of PCa (Mikolajczyk et al., 2004; Sokoll et al., 2008). 
The ratio of proPSA to fPSA has been claimed to improve specificity for PCa detection in the 
PSA range 2 to 4 g/L (Catalona et al., 2003; Sokoll et al., 2003). The level of BPSA in 
serum is associated with prostate volume (Naya et al., 2004) and is higher in BPH patients. 
The ratio of proPSA to BPSA improves detection of PCa in men with less than 15% fPSA 
(Khan et al., 2004). The concentration of intact PSA can be measured by an assay with a PSA 
antibody that does not recognize PSA nicked between amino acid 145-146. The ratio of intact 
PSA to fPSA is significantly higher in PCa than in BPH (Nurmikko et al., 2001; Steuber et 
al., 2002; Steuber et al., 2007a; Vickers et al., 2008). About 3% of fPSA in plasma is 
enzymatically active and thus only part of the active PSA in plasma forms complexes with 
serpins and A2M. Active PSA is of potential utility for detection of PCa (Niemela et al., 
2002). 
The carbohydrate structures in cancer cells are known to differ from those of 
nonmalignant cells, and this can be used for cancer diagnostics (Fukuda, 1996; Singhal & 
Hakomori, 1990). The glycan structures of PSA in serum, seminal plasma and LNCaP PCa 
cells are different (Ohyama et al., 2004; Okada et al., 2001; Peracaula et al., 2003; Prakash & 
Robbins, 2000). The content of 2,3-linked sialic acid in serum of PCa patients is lower than 
that in seminal plasma (Tabares et al., 2006) and potentially discriminates malignant from 
benign conditions (Tajiri et al., 2008). Reduced sialylation of tPSA is found in PCa, and 
measurement of PSA with 2,6-linked sialic acid in serum with a lectin immunosorbant assay 
improves detection of PCa compared to %fPSA (Meany et al., 2009).  
 
4.3.2 Age specific reference ranges 
 
Serum PSA level increases with age, presumably due to the increasing incidence of BPH 
among elderly men (Babaian et al., 1992; Verhamme et al., 2002). Age-specific reference 
ranges have been proposed to increase the sensitivity of detection in younger men and the 
specificity in older men (Table 5) (Morgan et al., 1996; Oesterling et al., 1993; Oesterling et 
al., 1995). However, this approach has been criticized for missing clinically significant 
cancers in older men (Borer et al., 1998; Catalona et al., 1994).  
 
4.3.3 PSA kinetics  
 
The long-term change in serum PSA is termed PSA velocity. An increase of serum PSA of 
more than 0.75 g/L per year is associated with increased risk of PCa (Carter et al., 1992a), 
and PSA velocity is useful for PCa detection (Carter & Pearson, 1993; Loeb et al., 2007; 
Punglia et al., 2007). PSA velocity can also indicate tumor aggressiveness and risk of 
mortality after radiation therapy (D'Amico et al., 2004; D'Amico et al., 2005; Loeb et al., 
2008; Partin et al., 1994; Robinson et al., 2008), but this has not been confirmed in other 
studies (Pinsky et al., 2007; Ulmert et al., 2008). 
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Table 5. Reference ranges for free, complexed and total PSA, and free-to-total, complexed-
to-total and free-to-complexed PSA ratios according to patient age (Oesterling et al., 1995). 
Reprinted with permission from Elsevier. 
  
 
PSA doubling time (PSADT) is defined as the time needed for the PSA value to 
double. PSADT is shorter in men with than without PCa (Raaijmakers et al., 2004; Spurgeon 
et al., 2007). A short PSADT following radiation therapy and radical prostatectomy is 
correlated with tumor aggressiveness (Leibman et al., 1998; Pruthi et al., 1997; Teeter et al., 
2008).  
The PSA concentrations in serum are influenced by individual biological variation, 
and measurement of PSA velocity and PSADT requires several determinations over a long 
time (Ornstein et al., 1997; Roehrborn et al., 1996; Soletormos et al., 2005). Optimal number 
and time of individual measurements are not known. Furthermore, differences between 
different PSA assays can result in an artificial PSA change (Link et al., 2004; Stephan et al., 
2006). Therefore the use of PSA kinetics is controversial (Ramirez et al., 2008; Vickers et al., 
2009).  
 
4.3.4 PSA density 
 
PSA density is the ratio of serum PSA to prostate volume estimated by TRUS. The PSA 
density is higher in men with PCa than in those with prostatitis and BPH (Benson et al., 1992; 
Kundu et al., 2007; Rietbergen et al., 1998; Veneziano et al., 1990). Some studies have 
reported that the transition zone volume more accurately predicts a positive biopsy than total 
prostate volume (Djavan et al., 1998; Kalish et al., 1994; Zlotta et al., 1997). However, this 
has not been confirmed in other studies (Brawer et al., 1993; Lin et al., 1998; Ohori et al., 
1995). Furthermore, the limited accuracy of TRUS affects the calculation of PSA density 
(Matlaga et al., 2003).  
 
4.3.5 Statistical and mathematical methods  
 
Multivariate analysis can be used to explain the relationship between diagnostic variables and 
the outcome variable. Different multivariate logistic regression (LR) models and artificial 
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neural networks (ANNs) have been developed to improve diagnostic accuracy for PCa 
detection (Carlson et al., 1998; Djavan et al., 2002; Finne et al., 2001; Kawakami et al., 2008; 
Stephan et al., 2005; Virtanen et al., 1999). ANNs can also predict the stage of PCa (Han et 
al., 2001; Tewari, 1997; Zlotta et al., 2003) and biochemical failure after radical 
prostatectomy (Potter et al., 1999; Poulakis et al., 2004; Ziada et al., 2001). This facilitates 
estimation of the need for adjuvant therapy (Potter et al., 1999; Poulakis et al., 2004; Ziada et 
al., 2001). The variables used include various molecular forms of PSA, clinical stage, age and 
prostate volume. 
A model using PSA concentration, clinical TNM stage, and biopsy Gleason score, 
called “Partin tables,” is widely used to predict pathological stage of PCa (Partin et al., 1997; 
Partin et al., 1993). Nomograms based on PCa biomarkers, clinical stage, and Gleason grade 
have been developed to predict PCa relapse after radical prostatectomy (Kattan et al., 1998; 
Kattan et al., 1999; Shariat et al., 2008; Stephenson et al., 2006b).  
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5. AIMS OF THE PRESENT STUDY  
 
The aim of the present study was to develop specific assays for detection of various forms of 
PSA in circulation and to evaluate their validity for diagnosis of prostate cancer.  
 
The specific aims were: 
 
1. To develop a novel monoclonal antibody and an immunoassay for PSA-ACT (I).  
2. To develop novel immunoassays using a peptide specifically reacting with active free PSA  
    (II, III). 
3. To develop a sensitive immunoassay for PSA-API based on proximity ligation (IV). 
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6. MATERIALS AND METHODS 
 
6.1 Serum samples (I, II, IV) 
 
Serum samples from men with or without evidence of cancer (I, II, IV), and from healthy 
females (I, II, IV) were obtained from the Department of Clinical Chemistry, Helsinki 
University Central Hospital. Serum samples  (IV) were obtained from 139 men participating 
in the Finnish Part of the European Randomized Screening for Prostate Cancer (Maattanen et 
al., 2001). All patient
 
samples were taken before initiation of therapy, and frozen once and 
stored
 
at -80°C until analyzed. The diagnoses
 
were based on histological analysis of tissue 
obtained by biopsy
 
or at surgery. Human seminal fluid was obtained from Department of 
Obstetrics and Gynecology, Helsinki University Central Hospital. 
 
6.2 Antibodies 
 
The antibodies used are listed in Table 6. 
 
6.2.1 Development of MAbs (I, IV) 
 
BALB/c mice were immunized with 10–30 g of PSA-ACT or PSA-API by intraperitoneal 
injection with Freund’s complete
 
adjuvant. A booster dose of 10 g was administered after
 
4 
weeks, with additional boosters of 100 and 150 g administered
 
1 and 2 days after the first 
booster dose, respectively. After
 
the final booster, the splenic lymphoid cells of the mice were
 
fused with the mouse myeloma cell P3x63-Ag8.653 (American Type
 
Culture Collection). The 
fused cells were harvested in HAT medium
 
supplemented with interleukin-6 for 4 weeks. 
Antibody production was evaluated by an in-house IFMA. MAbs were purified from cell 
culture fluid medium by protein G affinity
 
chromatography (Amersham Pharmacia Biotech 
AB, Uppsala, Sweden). 
 
Table 6. List of antibodies used. 
 
Antibody Specificity 
1
 Source 
2
 Used in 
5A10 Anti fPSA H. Lilja III 
9B10 Anti fPSA H. Lilja III 
4G10 Anti fPSA J. Leinonen II 
5C7 Anti fPSA and PSA-ACT J. Leinonen III 
2E9 Anti fPSA and PSA-ACT Perkin Elmer-Wallac III 
E91 Anti fPSA and PSA-ACT E. Paus III 
H50 Anti fPSA and PSA-ACT Abbott III 
9C5 Anti fPSA and PSA-ACT J. Leinonen III 
5E4 Anti fPSA and PSA-ACT J. Leinonen II, III, IV 
1D10 Anti complexed ACT L. Zhu I 
8G8 Anti API L. Zhu IV 
Rabbit anti PSA Anti fPSA and PSA-ACT DAKO I 
Rabbit anti ACT Anti ACT DAKO I 
Rabbit anti API Anti API DAKO IV 
1
 Details described in (Becker et al., 1999) 
2
 Details described in (Stenman et al., 1999b) and this thesis. 
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6.3 Chromatographic methods 
 
6.3.1 Gel filtration (I, II, IV) 
 
Gel filtration
 
was performed on a 1.6 x 60 cm Superdex-200 column (Amersham Pharmacia 
Biotech)
 
equilibrated with 50 mmol/L Tris-HCl buffer (pH 7.7) containing
 
150 mmol/L NaCl 
(Tris-buffered saline, TBS). The flow rate was 15
 
mL/h, and 2-mL fractions were collected 
into tubes containing
 
200 L of TBS with 5% bovine serum albumin (BSA) (Sigma, St. 
Louis, MO). 
 
6.3.2 Ion exchange chromatography  
6.3.2.1 Cation exchange chromatography (II, III)  
 
The sample diluted 10-fold with 50 mmol/L phosphate buffer, pH
 
5.6 (buffer A) was applied 
to a 1-ml Resource S column (Amersham
 
Pharmacia Biotech) equilibrated with buffer A.  
Proteins were eluted with a linear gradient
 
composed of 60 ml of buffer A and 60 ml of buffer 
A containing 0.5 mol/L NaCl. 
6.3.2.2 Anion exchange chromatography (I, IV)  
 
A 1-ml Resource Q column (Amersham Biosciences) was equilibrated with 10 mmol/L Tris-
HCl buffer containing 8 mmol/L sodium azide, pH 8.4 (buffer B). The serum sample was 
diluted 10-fold volume of buffer B and applied to the column. Proteins were eluted with a 
linear gradient composed of 60 ml of buffer B and 60 ml of buffer B containing 0.3 mol/L 
NaCl. 
 
6.3.3 Affinity chromatography (II, III) 
 
The sample was applied
 
to an immunoaffinity column prepared by coupling a monoclonal 
anti-PSA antibody (5E4 or 4G10) to CNBr-activated Sepharose (Amersham Pharmacia 
Biotech). The
 
column was washed with 30 bed volumes of 50
 
mmol/L Tris buffer containing 
0.5 mol/L NaCl (pH 8) or 50 mmol/L phosphate buffer (pH 5.6). Protein was eluted
 
with 
0.1% trifluoroacetic acid and neutralized with 1 mol/L Tris base. 
 
6.4 Production and purification of proteins 
 
6.4.1 Purification of PSA from seminal plasma (II) 
 
Seminal plasma was precipitated with ammonium sulfate at 25%
 
and 70% saturation. The 
precipitate obtained with 70% saturation was diluted and applied
 
to an affinity 
chromatography column with MAb 5E4. PSA was further
 
purified by ion-exchange 
chromatography on a Resource Q column. 
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6.4.2 Purification of proPSA from LNCaP cell medium (II, III) 
 
proPSA was purified from
 
LNCaP cell culture medium by immunoaffinity chromatography
 
with anti-PSA MAb 4G10. Affinity-purified
 
LNCaP PSA was further
 
separated by ion 
exchange chromatography on a Resource S column (Amersham
 
Pharmacia Biotech). The 
fraction containing proPSA was activated by treatment with bovine trypsin
 
(Sigma). 
 
6.4.3 Preparation of PSA-ACT, PSA-API and cathepsin G-ACT (I, IV) 
 
PSA-API, and PSA-ACT were prepared by incubating purified PSA with API (Athens 
Research and Technology Inc, Athens, GA), or ACT (Sigma) at
 
37 °C for 48 h. PSA-API or 
PSA-ACT were further separated by gel filtration on a Superdex-200 column (Amersham
 
Pharmacia Biotech). The cathepsin G-ACT complex
 
was prepared by incubating purified 
cathepsin G with ACT at
 
37 °C for 30 min.  
 
6.5 PSA-binding peptides (II, III) 
 
PSA-binding peptides were identified by screening phage display
 
peptide libraries (Koivunen 
et al., 1993; Koivunen et al., 1994; Wu et al., 2000). Two peptides, B-2 (CVFAHNYDYLVC) 
and C-4 (CVAYCIEHHCWTC), were constructed
 
as GST fusion proteins, expressed in 
Escherichia coli BL21
 
cells and purified by glutathione affinity chromatography (Amersham
 
Pharmacia Biotech) as described previously (Wu et al., 2000).  
 
6.6 Labeling and biotinylation of proteins  
 
Antibodies and other proteins were labeled with either Eu
3+
 or
 
Sm
3+
 chelates of N1-(p-
isothiocyanatobenzoyl)-diethyleneamine-N1,N2,N3,N3-tetraacetic
 
acid according to the 
manufacturer’s instructions (Perkin Elmer-Wallac, Turku, Finland) (I, IV). 
Biotinylation of antibodies with Sulfo-NHS-LC-biotin was performed according to the 
manufacturer’s instructions (Pierce, Rockford, IL) (III, IV). 
 
6.7 Measurement of enzymatic activity (II) 
 
Purified proPSA (100 ng) was incubated in microtiter wells
 
coated with monoclonal antibody 
5E4 for 1 h at 22 °C with slow shaking.
 
After washing of the wells twice, bound proPSA was 
activated
 
by addition of 10 ng of bovine trypsin (Sigma) in 200 L of
 
buffer (5% BSA in 
TBS)
 
and incubated for 20 min at 22 °C. After washing, a fluorescent peptide substrate 
(Denmeade et al., 1997) (Enzyme Systems Products, Livermore, CA) was added to
 
a final 
concentration of 400 mol/L, and the absorbance
  
(excitation wavelength at 355 and emission 
wavelength at 460 nm) was monitored for 120 min in a Victor 1420 Multilabel
 
counter 
(Perkin Elmer-Wallac).  
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6.8 Measurement of fPSA and tPSA (I, II, III, IV) 
 
fPSA and tPSA were measured by a dual-label IFMA. Twenty five L of standards from the 
ProStatus PSA fPSA/tPSA kit (Perkin Elmer-Wallac) and samples together with 200 L of 
assay buffer (Perkin Elmer-Wallac) were added to microtiter plate wells coated with MAb 
H117 or MAb 5E4.  After 1 h incubation at room temperature with slow shaking, the plates 
were washed twice. 200 L of assay buffer containing Eu
3+
-labeled MAb 5A10 and Sm
3+
-
labeled MAb H50 (Perkin Elmer-Wallac) were added. After incubation for 2 h at room 
temperature with shaking, unbound antibodies were removed by washing four times. 200 L 
of enhancement solution (Perkin Elmer-Wallac) was added and the fluorescence was 
measured after incubation for 5 min. All samples were tested in duplicate. 
 
6.9 Immunoblotting (IV) 
 
SDS-PAGE was performed in 2-mm thick, 3-16% gradient polyacrylamide gels. Proteins 
were transferred electrophoretically to nitrocellulose membrane and incubated either with 
MAb 5E4 or a MAb against API (Table 6). Bound antibodies were detected with horseradish 
peroxidase-conjugated polyclonal rabbit anti mouse IgG (DAKO, Glostrup, Denmark) using 
3,3’-diaminobenzidine tetrahydrochloride as a substrate. 
 
6.10 Construction of proximity probes (III, IV) 
 
Proximity probes with either free 3' or 5' end were prepared by conjugating
 
thiol-modified 
oligonucleotides to maleimide-derivatized streptavidin
 
(Sigma). The conjugates were 
subsequently reacted with biotinylated
 
antibodies or biotinylated peptides as described 
(Gullberg et al., 2004). The oligonucleotide
 
sequences were as follows:  
5' free STV, 5'P-
TCGTGTCTAAAGTCCGTTACCTTGATTCCCCTAACCCTCTTGAAAAATTCGGCATC
GGTGA-3';
  
3' free STV, 5'-
CGCATCGCCCTTGGACTACGACTGACGAACCGCTTTGCCTGACTGATCGCTAAAT
CGTG-3'OH. 
 
6.11 Assay development   
 
6.11.1 Time-resolved IFMAs for fPSA/tPSA and the PSA-ACT complex (I) 
 
Sera with high PSA concentrations were pooled and used as a
 
calibrator (the concentration 
range of the calibrators was 0.8-120 g/L calculated on the basis of tPSA). Calibrators or
 
serum samples (25 L) were added to wells coated with
 
MAb H117, followed by 100 L of 
assay buffer (Perkin Elmer-Wallac).
 
After incubation for 1 h at room temperature with 
shaking, the
 
wells were washed twice. In the double-label assays for PSA-ACT and tPSA, 200 
L of assay buffer containing
 
tracer antibodies, Eu
3+
-1D10 and Sm
3+
-H50, were added 
together. However, in the double-label assay for fPSA and PSA-ACT, there was interference 
between the Sm
3+
-1D10 and the Eu
3+
-5A10. If they were added simultaneously or the Sm
3+-
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1D10 was added first and the Eu
3+
-5A10 1 h later, there was 10-fold increase in the 
background of the fPSA assay. This problem was eliminated when the Eu
3+
-5A10 was added 
first and incubated for 1 h before addition of Sm
3+
-1D10. After further
 
incubation for 2 h and 
washing four times, 200 L of enhancement solution
 
(Perkin Elmer-Wallac) was added to the 
wells. After shaking
 
for 5 min at room temperature, the fluorescence was measured with a 
Victor 1420 Multilabel counter (Perkin Elmer-Wallac).  
 
6.11.2 Immunopeptidometric assay (IPMA) (II) 
 
Pure enzymatically active PSA was used as a calibrator. 25 L of samples and calibrators in 
200
 
L of assay buffer [50 mmol/L Tris-HCl (pH 7.7), 150 mmol/L
 
NaCl, 67 mol/L BSA, 1 
mol/L bovine
 
IgG] were added to MAb 5E4-coated wells and incubated for 1
 
h at 22 °C. 
After incubation, the wells
 
were washed, and 1 g of GST fusion protein in 200 L of
 
assay 
buffer was added. After incubation for 60 min at 22 °C,
 
the wells were washed, and 50 ng of 
Eu
3+
-labeled anti-GST
 
antibody (Amersham Pharmacia Biotech) in 200 L of assay
 
buffer 
was added and incubated for 60 min. The wells were washed
 
four times, and enhancement 
solution (Perkin Elmer-Wallac) was added. Slow shaking was used during all
 
incubations. 
After 5 min, time-resolved fluorescence was measured. 
   
    
6.11.3 Immunoassay based on proximity ligation (III, IV) (Fig. 5) 
 
In the assay, 1 g of monoclonal anti-PSA antibody 5E4 in 50 l of PBS was allowed to 
adsorb to ABI PRISM optical tubes (Applied Biosystems, Foster City, CA) overnight at 4 °C. 
Unadsorbed antibodies were washed away with PBS and the non-specific binding sites of the 
wells were saturated with assay buffer (1% BSA in PBS) overnight at 4 °C. 50 L of 
standards or samples in duplicate were added to the tubes. After incubation for 1 h at room 
temperature, the tubes were washed twice with PBS and 50 L of assay buffer and proximity 
probes (100 pmol/L each) were added. After incubation for 2 h at room temperature, unbound 
probes were removed by washing twice with 200 L of Milli-Q water. The ligation and 
TaqMan PCR mix (50 L) (Gullberg et al., 2004) was added. Oligonucleotide sequences were 
as follows: Connector oligonucleotide, 5'-TACTTAGACACGACACGATTTAGTTT-3'; 
forward
 
primer, 5'-CATCGCCCTTGGACTACGA-3'; reverse primer, 5'-
GGGAATCAAGGTAACGGACTTTAG-3'.
 
After ligation for 5 min at room temperature the 
tubes were transferred to a real-time PCR instrument for temperature cycling at 95 °C for 2 
min, followed by 95 °C for 15 s and 60 °C for 60 s, repeated 40 times (Applied Biosystems 
PRISM 7000). The ligation and TaqMan PCR mix used in the study III were provided by 
Olink AB (Uppsala, Sweden). 
 
6.12 Statistical analyses 
 
The detection limits for assays were calculated from the mean concentration plus two standard 
deviations of the signal in female sera with unmeasurable PSA concentrations (I, IV) or in 
assay buffer (II, III). Pearson parametric correlation coefficients were used to describe
 
the 
correlation between different assays (I).  The correlation between the IFMA and proximity 
ligation assay was determined by linear regression analysis (IV). Differences in 
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concentrations of various forms of PSA between PCa patients and controls were
 
calculated 
with the Mann-Whitney U-test (I, IV). Differences in specificity at various sensitivities were 
compared
 
by the McNemar test (I, IV). Receiver operation curve (ROC) analysis was used to 
estimate the diagnostic validity of various tests (I, IV). Statistical analysis was performed with 
SPSS 15.0 for Windows (SPSS. Inc., Chicago, IL). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Principle of proximity ligation assay. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35 
7. RESULTS 
 
7.1 Characterization of MAbs 
7.1.1 Development of MAbs to ACT (I) 
 
Three MAbs (1D10, 8D2, and 1E2) reacted more
 
strongly with PSA-ACT than with free 
ACT, while they did not react with fPSA
 
or PSA-API. These MAbs recognized the captured 
cathepsin G-ACT
 
complex. Of these, MAb 1D10 showed the lowest reactivity with free ACT 
and cathepsin
 
G-ACT as compared to PSA-ACT (Fig. 6).
 
MAb 1D10 was selected as a tracer 
in the PSA-ACT assay. 
 
 
Figure 6. Reactivity of anti-ACT MAbs 
with cathepsin G-ACT (CatG-ACT) and 
PSA-ACT complexes. 
 
7.1.2 Development of MAbs to API (IV) 
 
Four MAbs (8G8, 8E8, 2E11 and 13D10) reacted with both API and PSA-API, but not with 
PSA. This was confirmed both by Western immunoblotting (Fig. 7) and by IFMA using Eu
3+
-
labeled PSA and API. MAb 8G8 showed the highest affinity and was selected for the PSA-
API assay. The specificity of MAb 8G8 was further tested with purified fPSA, hK2, PSA-
API, API, PSA-ACT and trypsin-2-API in an IFMA using MAb 5E4 as a capture antibody. 
The results showed that the combination of MAb 5E4 and Eu
3+
-labeled MAb 8G8 recognized 
only PSA-API. 
 
Figure 7. Immunoblotting with anti-API 
MAb 8G8 (A) and anti-PSA MAb 5E4 
(B). Lane M, molecular mass markers; 
Lane 1, PSA; Lane 2, API; Lane 3, PSA-
API. 
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7.2 Assay performance 
 
7.2.1 Dual-label immunoassay for measurement of PSA-ACT with either fPSA or tPSA (I) 
 
In the dual-label assay for PSA-ACT and
 
fPSA, the detection limit was 0.05 g/L for PSA-
ACT and 0.004
 
g/L for fPSA, respectively. In the dual-label assay for PSA-ACT and
 
tPSA, 
the detection limits were 0.03 g/L for PSA-ACT
 
and 0.02 g/L for tPSA. The intra-assay 
coefficients of variation (CVs) and inter-assay CVs were
 
from 0.4% to 6.1% for all assays 
(Table 7). The mean analytic recovery of fPSA was 93.3% (range, 80.6-106.5%),
 
and that of 
PSA-ACT was 99% (97.5-102.8%), respectively.  
For fPSA, the correlation between the double-label assays for
 
fPSA/PSA-ACT and 
fPSA/tPSA was: y =1.15x - 0.13 (r = 0.98). The
 
correlation between PSA-ACT concentrations 
measured by the fPSA/PSA-ACT
 
and PSA-ACT/tPSA assays was: y = 1.03x + 0.15 (r = 
0.99). The
 
calculated concentrations of tPSA based on the sum of fPSA and
 
PSA-ACT 
obtained with the fPSA/PSA-ACT assay and those measured
 
by the fPSA/tPSA and PSA-
ACT/tPSA assays also correlated well
 
(y = 1.07x - 0.27; r = 0.99 and y = 1.07x - 0.29; r = 
0.99). 
 
Table 7. Precision and reproducibility of double-label assays for tPSA/fPSA and PSA-ACT. 
 
        CV%   
 tPSA fPSA PSA-ACT PSA-ACT 
/tPSA 
fPSA/ 
PSA-ACT 
Dual-label assays for PSA-ACT/tPSA      
Sample 1 (5.3 g/L)      
Intra-assay 2 1.5 2.2 0.8 2.9 
Inter-assay 3.2 3.9 3 0.4 3.6 
Sample 2 (13.5 g/L) 
     
Intra-assay 3.1 3.1 3.8 0.4 6.1 
Inter-assay 2.7 4.1 2.3 0.7 4.8 
 
     
Dual-label assay for fPSA/PSA-ACT 
     
Sample 1 (5.3 g/L) 
     
Intra-assay 2.5 2.6 3.2 1.9 4.6 
Inter-assay 3.5 3.5 3.6 3.5 2.1 
Sample 2 (13.5 g/L) 
     
Intra-assay 3 3.3 3.2 2.4 3.2 
Inter-assay 3 2.3 3.6 1.2 5.2 
 
7.2.2 IPMA for enzymatically active PSA (II) 
 
The detection limit of the IPMA was 0.6 g/L. The intra-
 
and interassay CVs of the assay 
were 7-12%
 
and 8-13%, respectively, at concentrations
 
of 2-100 g/L. The reactivities of the 
PSA isoenzymes (A-E), which display
 
variable enzyme activities, were analyzed by the 
IPMA. GST-peptides
 
B-2 and C-4 bound equally to
 
the intact isoenzymes A and B (defined as 
100%), whereas the
 
response was 25%, 15%, and 7% with PSA isoenzymes C, D, and
 
E, 
respectively (Fig. 8). proPSA purified from LNCaP cell
 
culture medium showed low 
enzymatic activity. After activation by trypsin, the activity increased. Approximately 6-9% of 
proPSA was recognized
 
by the IPMA, and after activation with trypsin recognition increased
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to 71-88% compared with that of PSA-B. 
 
 
Figure 8. Reactivity of various PSA 
isoenzymes in the IPMA. 
 
7.2.3 Proximity ligation assay for active PSA (III) 
 
The detection limit of the assay was 0.07 g/L and the dose response was linear up to a 
concentration of 25 g/L. The inter-assay CVs were 23.5% and 19.6%, and intra-assay CVs 
were 21.7% and 14.4% at PSA concentrations of 0.56 and 3.18 g/L, respectively. The assay 
did not cross-react with proPSA or with hK2. 
 
7.2.4 Measurement of the complex between PSA and API by proximity ligation (IV) 
 
The analytical detection limit was 6.6 ng/L. The intra-assay CVs were 18.3 and 17.8% and the 
inter-assay CVs 20.6 and 19.0% in serum with PSA-API concentrations of 0.25 and 1.22 
g/L, respectively.  
Pure PSA-API was diluted to concentrations of 0.02-4.98 g/L with 1% BSA in PBS 
and measured by IFMA and by the proximity ligation assay for PSA-API. The correlation 
between the results was good (y=1.04x+0.13, R
2
 = 0.98).  
One g of pure PSA-B was added to 0.5 ml of female serum. After incubation for 48 
h, the sample was subjected to anion exchange chromatography. The fractions were analyzed 
for fPSA and tPSA with an IFMA and PSA-API with proximity ligation assay. A minor peak 
containing PSA-API was separated from the major peaks containing fPSA and PSA-ACT 
(Fig. 9).  
 
7.3 Molecular forms of PSA in serum 
 
7.3.1 PSA-ACT (I) 
 
Sera from patients with or without PCa with PSA concentrations
 
in the range 2-20 g/L were 
measured with dual-label IFMA. The median concentration of PSA-ACT was 3.67 g/L in 
patients without PCa and 3.93 g/L in PCa men, while the proportion of fPSA to PSA-ACT 
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(%fPSA/PSA-ACT) was 31.6% and 24.8%, respectively. The apparent mean value of PSA-
ACT in 84 female sera was 0.02 g/L, which is below the detection limit of the assay.
 
None 
of 84 values exceeded the detection limit. 
 
 
Figure 9. Separation of three major 
forms of PSA in plasma by anion-
exchange chromatography. 
 
 
7.3.2 Active PSA (II) 
 
Active PSA in
 
serum samples containing above 10 g/L fPSA was analyzed by IPMA. The 
concentrations
 
measured corresponded to 1–10% of the fPSA concentration. No PSA was 
detected by the IPMA in 10 female sera. 
 
7.3.3 PSA-API (IV) 
 
Samples with tPSA concentrations of 4.01-9.78 g/L were used to evaluate the validity of 
PSA-API. The median concentration of PSA-API was 0.17 g/L in screening negative men 
and 0.16 g/L in men diagnosed with PCa, while the median %PSA-API was 3.3% (range, 
0.38-14.4%) in screening negative men and 2.8% (range, 0.23-13.4%) in PCa cases.  
 
7.4 Clinical validity of PSA complexes  
 
7.4.1 PSA-ACT (I) 
 
The area under the curve (AUC) for %fPSA/PSA-ACT was higher than those for either tPSA 
or PSA-ACT alone, and their difference
 
was highly significant (P <0.001). There were no 
significant differences
 
in AUC values between %fPSA, %PSA-ACT,
 
and %fPSA/PSA-ACT. 
The AUC values for PSA-ACT alone or the calculated
 
values for complexed PSA (tPSA 
minus fPSA) were not significantly larger than those for tPSA (Fig. 10). 
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Figure 10. ROC curves for individual analytes and ratios based on 35 PCa and 90 control 
samples with PSA concentrations of 2-20 g/L.  
 
7.4.2 PSA-API (IV) 
 
The AUC for %PSA-API was 0.546 while that for tPSA was 0.536. The AUC value of 
%fPSA was 0.710, which was significantly greater than that of tPSA (P= 0.011). Because 
both %fPSA and %PSA-API were lower in cancer cases than in controls, we calculated 
whether the sum of them provided further improvement. The AUC value for sum of %fPSA 
plus %PSA-API was 0.723, which was slightly larger than that for %fPSA alone and 
significantly larger than that for tPSA (P =0.006). 
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8. DISCUSSION 
 
PCa is the most common cancer and the second leading cause of cancer-related deaths in 
Western men. Early detection
 
and treatment of PCa is thought to reduce mortality of PCa 
(Espey et al., 2007; Jemal et al., 2004; Martin et al., 2008). Because the serum concentrations 
of PSA increase about 5-10 years before PCa surfaces clinically, it is possible to detect PCa at 
an early and potentially curable stage (Gann et al., 1995; Stenman et al., 1994). Thus PCa is a 
potential screening target. However, the first results from PCa screening studies show that the 
reduction of mortality is small (Schroder et al., 2009) or not significant (Andriole et al., 
2009). Thus, better screening strategies and tumor markers are needed.  
PSA is organ-specific but not cancer-specific, and therefore benign prostatic diseases 
can also cause an increase of PSA in circulation. Thus only about one third of patients with 
moderately elevated PSA level (4-10 g/L) have a positive biopsy while the rest are false 
positives (Andriole et al., 2005; Catalona et al., 1998). On the other hand, the biopsy results 
may be false negative in cases of small local cancer, especially if only a limited number of 
biopsy cores are taken. Improved diagnostic accuracy of the PSA test is therefore needed, and 
this can be achieved by measurement of various molecular forms of PSA (Lilja et al., 2008). 
Measurement of PSA-ACT, fPSA, PSA-API, PSA-A2M, enzymatically active PSA and 
proPSA have all been shown to improve the clinical validity of PSA, and assays for fPSA are 
widely available. However, assays for many other forms are hampered by various technical 
problems. Thus, the assays for PSA-ACT and PSA-API tend to have a high nonspecific 
background, while assay of enzymatically active PSA has been limited by lack of specific 
antibodies (Stenman et al., 1991; Zhang et al., 1997).Various methods have previously been 
used to reduce the background in assays for PSA-ACT, e.g., addition of milk casein (Wu et 
al., 1998) and heparin 
 
into the assay buffer (Pettersson et al., 1995) or use of a PSA-ACT-
specific MAb (Wang et al., 1999). In a previous assay for PSA-API, the non-specific 
background was measured in a well coated with an unrelated antibody and the fluorescence in 
this well was subtracted from that in the corresponding assay well (Finne et al., 2000b). 
However, these methods were only partially successful. An alternative approach is to measure 
these two complexed forms of PSA together in an assay for complexed PSA (cPSA) (Allard 
et al., 1998). This assay measures PSA-ACT and PSA-API together, which is a principal 
disadvantage because PSA-ACT increases while PSA-API decreases in PCa.  
 
8.1 Dual-label immunoassays for PSA-ACT and fPSA/tPSA (I) 
 
Measurement of PSA-ACT and calculation of %PSA-ACT improves the
 
discrimination 
between PCa and benign prostatic disease compared
 
with tPSA (Lilja et al., 1991; Stenman et 
al., 1991) but previously available assays were hampered by a background
 
caused by 
nonspecific binding to the solid phase of a large excess of uncomplexed ACT and other ACT-
protease complexes (Leinonen et al., 1993). To reduce this problem we developed MAbs that 
preferentially detected PSA-ACT but not free ACT or other ACT complexes. Antibody 1D10 
showed good specificity and dual label assays with this MAb as a tracer were developed to 
simultaneously measure PSA-ACT and tPSA or fPSA. By these assays PSA-ACT was 
undetectable in female sera showing that the problem with nonspecific background had been 
eliminated. The correlation between PSA-ACT measured with dual assay for PSA-ACT and 
tPSA or dual assay for fPSA and PSA-ACT was excellent. An advantage of the dual assay is 
that tPSA and PSA-ACT, or fPSA and PSA-ACT are measured in the same assay, and the 
imprecision caused by pipetting
 
errors is reduced which improves measurement of the ratios. 
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ROC analysis revealed that %PSA-ACT gives the same discrimination between
 
cancers and 
controls as %fPSA. All calculated ratios, i.e., %fPSA/PSA-ACT, %PSA-ACT,
 
and %fPSA, 
provided the same improvement in cancer specificity.
 
This finding confirms that the assays 
and the calculated ratios
 
perform as theoretically expected. 
 
8.2 Proximity ligation assay for PSA-API (IV) 
 
Assay of PSA-API is complicated both by the high non-specific background and by the low 
concentrations of PSA-API in serum (Zhang et al., 1999). Proximity ligation assay has been 
shown to be an ultrasensitive and highly specific method for detection of proteins 
(Fredriksson et al., 2002; Gullberg et al., 2004). The assay uses a pair of DNA probes bound 
to matched antibodies. When these antibodies bind to a target protein, the ends of the 
oligonucleotides are brought into proximity and can be hybridized with a probe that is 
complementary to the antibody bound oligonucleotides. The DNA strand formed in the 
ligation reaction is amplified and quantified by a real time PCR. The need for binding of both 
probes in close proximity to each other can be expected to prevent detection of API 
nonspecifically bound to the solid phase and this should reduce assay background. 
Furthermore, DNA amplification increases assay sensitivity.  
We therefore decided to develop a sensitive and specific immunoassay for PSA-API 
based on proximity ligation. To improve sensitivity we developed a specific MAb to API 
(8G8) and used it as a probe. In the assay, PSA-API was captured to the solid phase by a 
MAb against tPSA and detected by two biotinylated MAbs, MAb 8G8 and MAb against 
tPSA, which were bound to streptavidin carrying the DNA probes. Simultaneous binding of 
these MAbs to the PSA-API complex brought the DNA strands close to each other allowing 
their ligation and thereafter amplification by real time PCR. The detection limit of assay was 
0.64 ng/L, which is about 10-fold better than in a previous IFMA (Finne et al., 2000b). The 
use of 3 rather
 
than 2 antibodies has been shown to enhance specificity and
 
sensitivity also in 
other proximity ligation assays (Gustafsdottir et al., 2006; Schallmeiner et al., 2007). The 
concentrations of PSA-API in female sera were undetectable, showing that the problem with 
nonspecific background caused by adsorption of API to the solid phase had been eliminated. 
PSA-API could thus be detected in plasma with PSA concentrations of 4-10 g/L.  
Correlation between results obtained by IFMA and by the proximity ligation assay 
was good and separation of various PSA complexes by ion exchange chromatography showed 
that the new assay specifically recognized PSA-API. The imprecision of our assay was higher 
than that of conventional immunoassays, which has been reported for other immunoassays 
utilizing PCR amplification (Lind & Kubista, 2005; Niemeyer et al., 2007).  
Serum samples from PCa patients and controls with tPSA concentrations of 4-10 g/L 
were used to evaluate the clinical utility of PSA-API. As shown in our earlier study, %PSA-
API tended to be lower in sera from men with PCa than in controls. The AUC value for 
%PSA-API improved discrimination between cancer cases and controls as compared to tPSA, 
but %fPSA was clearly superior to %PSA-API. However, the effect of %fPSA and %PSA-
API was additive and the diagnostic validity was improved by calculating the sum of these 
two variables. The improvement was modest but it was similar to that observed in our earlier 
study (Finne et al., 2000b) and similar to the improvement obtained by combining %fPSA 
with assay of hK2 (Steuber et al., 2007b). 
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8.3 Assays for enzymatically active PSA (II, III) 
 
Enzymatically active free PSA is of potentially diagnostic value (Niemela et al., 2002), but we 
have not obtained any antibody that specifically recognizes active PSA. We therefore 
developed an immunopeptidometric assay using as a tracer a peptide binding to active PSA 
(II). A MAb against tPSA was used to capture all isoforms of PSA and active PSA was 
detected with peptides that were expressed together with GST as fusion proteins (Wu et al., 
2000). Bound peptide was detected by time-resolved fluorometric assay with a Eu
3+
 labeled 
anti GST antibody. The assays, using peptides B-2 and C-4, detected the various seminal 
plasma PSA isoenzymes with variable enzymatic
 
activities to an extent corresponding to their
 
enzymatic activities. proPSA
 
was not recognized by this assay, but after activation with 
trypsin it reacted in the assay. The detection limit of the assay, 0.6 g/L, enabled 
measurement of active PSA in samples with elevated PSA concentrations. 
Fractionation of serum with a high PSA concentration by gel filtration and 
measurement of
 
the fractions by the IPMA showed that approximately 10% of fPSA was 
enzymatically active. Furthermore, direct assay of sera from PCa
 
patients showed that 1–10% 
of fPSA was enzymatically active in spite of the
 
large excess of protease inhibitors in plasma. 
Previously about 3% of fPSA in circulation has been found to be enzymatically
 
active 
(Niemela et al., 2002). This study shows that peptides can be used together with antibodies for 
development of novel immunoassays, but the IPMA is not sensitive
 
enough for measurement 
of active PSA in sera with the moderately
 
increased concentrations that are typically present at 
early
 
stages of PCa. 
To increase assay sensitivity, we developed an immunoassay for active PSA based on 
proximity ligation (III). A biotinylated peptide recognizing active PSA and a MAb against 
tPSA were used to construct a pair of probes, which detected active PSA captured by another 
MAb to tPSA. The detection limit of this assay was 0.07 g/L, which was ten-fold better than 
that of the IPMA. hK2, which has about 80% amino acid sequences identity with PSA, and 
proPSA were not detected with this assay. Thus this assay is of potential utility for evaluation 
of the utility of active PSA for differentiation between PCa and benign prostatic diseases.  
In comparison with other proximity ligation assays with very high sensitivity 
(Gullberg et al., 2004; Schallmeiner et al., 2007), the relatively moderate improvement in the 
sensitivity of this assay was likely due to the low affinity of the peptide for PSA, i.e., 100–
1000-fold lower than that of high-affinity antibodies. It has been shown that probe affinity 
and assay sensitivity are strongly correlated (Gullberg et al., 2004). Like in the PSA-API 
assay, the precision of the assay was inferior to that of conventional immunoassays.  
A number of detection technologies have been used to develop very sensitive assays 
for PSA and other proteins occurring at very low concentrations, i.e, in some cases in the 
range 0.001 ng/L (Table 4). Most of these require the use of custom built instruments and 
unique chemicals, whereas assay based on proximity ligation uses readily available 
instruments and chemicals. Proximity ligation has been used to establish an extremely 
sensitive assay for fPSA, but we did not achieve a similar sensitivity for PSA-API and 
enzymatically active PSA.  However, the assays developed had other unique properties that 
have not been obtained before with other approaches. These properties can be utilized to 
develop other assays for problematic analytes. 
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9. CONCLUSIONS 
 
We developed novel immunoassays for measurement of PSA-ACT and PSA-API in serum 
with low PSA levels. Measurements of these together with fPSA and %fPSA improve the 
diagnostic accuracy for PCa. IPMA is a new assay principle, by which enzymatically active 
PSA could be detected by utilizing a PSA-binding peptide. Assays using peptides with unique 
selectivity are potential tools for measurement of proteins for which antibodies cannot be 
obtained. Proximity ligation can be used to improve sensitivity of conventional assays, and 
this principle is also useful for reduction of the unspecific background. 
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